Sex hormones play a role in both the risk and the prognosis of multiple sclerosis (MS). Considering all stages of women’s reproductive life, data regarding the influence of menopause on MS and vice versa are scarce.
Objective:
The aim of this study was to review the evidence addressing the relationship between menopause and MS.
Methods:
A literature search through PubMed was conducted, selecting studies that assessed (1) the influence of menopause in the MS course, (2) the influence of MS and disease-modifying drugs (DMD) on the development of menopause and (3) the effect of hormone replacement therapy (HRT) on symptoms of menopausal MS patients.
Results:
(1) Most studies suggest menopause may transitorily aggravate MS symptoms. Two studies found an inflexion point on the Expanding Disability Status Scale (EDSS) with clinical worsening during the menopausal transition. Another study considering full EDSS trajectories from clinically isolated syndrome to postmenopause did not find such an EDSS inflection; (2) MS and DMD do not seem to alter the age of menopause onset; and (3) HRT in menopausal MS patients has not shown consistent benefits.
Conclusion:
Menopause seems to be associated with transient symptom worsening, but the existence of an inflection in disability progression is still controversial. Properly designed studies are necessary to achieve conclusive results.
DobsonRGiovannoniG.Multiple sclerosis – A review. Eur J Neurol2019; 26(1): 27–40.
2.
HohlfeldRDornmairKMeinlE, et al. The search for the target antigens of multiple sclerosis, part 1: Autoreactive CD4+ T lymphocytesas pathogenic effectors and therapeutic targets. Lancet Neurol2016; 15(2): 198–209.
3.
YsrraelitMCCorrealeJ.Impact of sex hormones on immune function and multiple sclerosis development. Immunology2019; 156(1): 9–22.
4.
BoveRChitnisT.The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler2014; 20(5): 520–526.
5.
McCombePAGreerJM.Female reproductive issues in multiple sclerosis. Mult Scler2013; 19(4): 392–402.
6.
BoveR.Women’s Issues in Multiple Sclerosis. Semin Neurol2016; 36(2): 154–162.
7.
ZuluagaMOtero-RomeroSRoviraA, et al. Menarche, pregnancies and breastfeeding are low impact prognostic factors in multiple sclerosis. Neurology2019; 92(13): 1507–1516.
8.
AlonsoAJickSSOlekMJ, et al. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol2005; 62(9): 1362–1365.
9.
GhislettiSMedaCMaggiA, et al. 17beta-estradiol inhibits inflammatorygene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol2005; 25(8): 2957–2968.
10.
BoulwareMIKentBAFrickKM.The impact of age-related ovarian hormone loss on cognitive and neural function. Curr Top Behav Neurosci2012; 10: 165–184.
11.
DhandapaniKMBrannDW.Role of astrocytes in estrogen-mediated neuro-protection. Exp Gerontol2007; 42: 70–75.
12.
NilsenJChenSIrwinRW, et al. Estrogen protects neuronalcells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neurosci2006; 7: 74.
13.
ChristiansonMSMensahVAShenW.Multiple sclerosis at menopause: Potential neuroprotective effects of estrogen. Maturitas2015; 80(2): 133–139.
14.
KatoITonioloPAkhmedkhanovA, et al. Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol1998; 51(12): 1271–1276.
15.
HarlowSDGassMHallJE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab2012; 97(4): 1159–1168.
16.
FreemanEWSammelMDGraciaCR, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril2005; 83(2): 383–392.
17.
BurgerHGHaleGEDennersteinL, et al. Cycle and hormone changes during perimenopause: The key role of ovarian function. Menopause2008; 15(4Pt 1): 603–612.
18.
RandolphJFJrZhengHSowersMR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: Effect of age at the final menstrual period. J Clin Endocrinol Metab2011; 96(3): 746–754.
19.
ThurstonRCJoffeH.Vasomotor symptoms and menopause: Findings from the Study of Women’s Health across the Nation. Obstet Gynecol Clin North Am2011; 38: 489.
20.
RandolphJFJrSowersMBondarenkoI, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab2005; 90(11): 6106–6112.
21.
HarshVMeltzer-BrodySRubinowDR, et al. Reproductive aging, sex steroids, and mood disorders. Harv Rev Psychiatry2009; 17(2): 87–102.
22.
SoaresCN.Depression and menopause: Current knowledge and clinical recommendations for a critical window. Psychiatr Clin North Am2017; 40(2): 239–254.
23.
MarrieRAHorwitzRCutterG, et al. The burden of mental comorbidity in multiple sclerosis: Frequent, underdiagnosed, and undertreated. Mult Scler2009; 15(3): 385–392.
24.
UlmstenU.Some reflections and hypotheses on the pathophysiology of female urinary incontinence. Acta Obstet Gynecol Scand Suppl1997; 166: 3–8.
25.
HeidariMGhodusiMRezaeiP, et al. Sexual function and factors affecting menopause: A systematic review. J Menopausal Med2019; 25(1): 15–27.
26.
MohammadiKRahnamaPMoayed MohseniS, et al. Determinants of sexual dysfunction in women with multiple sclerosis. BMC Neurol2013: 13(1): 83.
27.
GromischESSchairerLCPasternakE, et al. Assessment and treatment of psychiatric distress, sexual dysfunction, sleep disturbances, and pain in multiple sclerosis: A survey of members of the consortium of multiple sclerosis centers. Int J MS Care2016; 18(6): 291–297.
28.
DomingoSKinzyTThompsonN, et al. Factors associated with sexual dysfunction in individuals with multiple sclerosis: Implications for assessment and treatment. Int J MS Care2018; 20(4): 191–197.
29.
WeberMTRubinLHMakiPM.Cognition in perimenopause: The effect of transition stage. Menopause2013; 20(5): 511–517.
30.
BhattaSBlairJACasadesusG.Luteinizing hormone involvement in aging female cognition: Not all is estrogen loss. Front Endocrinol (Lausanne)2018; 9: 544.
31.
BrancoMRuanoLPortaccioE, et al. Aging with multiple sclerosis: Prevalence and profile of cognitive impairment. Neurol Sci2019; 40: 1651–1657.
32.
GrzegorskiTLosyJ.Cognitive impairment in multiple sclerosis – A review of current knowledge and recent research. Rev Neurosci2017; 28(8): 845–860.
33.
CampbellJRashidWCercignaniM, et al. Cognitive impairment among patients with multiple sclerosis: Associations with employment and quality of life. Postgrad Med J2017; 93(1097): 143–147.
34.
NaessenTLindmarkBLarsenHC.Hormone therapy and postural balance in elderly women. Menopause2007; 14(6): 1020–1024.
35.
CangussuLMNahas-NetoJPetri NahasEA, et al. Evaluation of postural balance in postmenopausal women and its relationship with bone mineral density – A cross sectional study. BMC Musculoskelet Disord2012; 13: 2.
36.
TyblovaMKalincikTZikanV, et al. Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. Eur J Neurol2015; 22(4): 624–632.
37.
BoveRChitnisTHoutchensM.Menopause in multiple sclerosis: Therapeutic considerations. J Neurol2014; 261(7): 1257–1268.
38.
SmithRStuddJW.A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J R Soc Med1992; 85(10): 612–613.
39.
HolmqvistPWallbergMHammarM, et al. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas2006; 54(2): 149–153.
40.
BoveRHealyBCSecorE, et al. Patients report worse MS symptoms after menopause: Findings from an online cohort. Mult Scler Relat Disord2015; 4(1): 18–24.
41.
BoveRHealyBCMusallamA, et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler2016; 22(7): 935–943.
42.
BoveRVaughanTChitnisT, et al. Women’s experiences of menopause in an online MS cohort: A case series. Mult Scler Relat Disord2016; 9: 56–59.
43.
LadeiraFSalavisaMCaetanoA, et al. The influence of menopause in multiple sclerosis course: A Longitudinal Cohort Study. Eur Neurol2018; 80(3–4): 223–227.
44.
BaronciniDAnnovazziPODe RossiN, et al. Impact of natural menopause on multiple sclerosis: A multicentre study. J Neurol Neurosurg Psychiatry2019; 90(11): 1201–1206.
45.
Otero-RomeroSRoviraAZuluagaMI, et al. Impact of oral contraceptives and menopause on MS risk and prognosis: Results from the Barcelona CIS cohort. París: ECTRIMS, 2017, p. 893.
46.
KatoITonioloPAkhmedkhanovA, et al. Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol1998; 51(12): 1271–12764.
47.
JacobsenBKHeuchIKvaleG.Age at natural menopause and all-cause mortality: A 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol2003; 157(10): 923–929.
48.
Türk BörüÜKöseoğlu ToksoyCBölükC, et al. Effects of multiple sclerosis and medications on menopausal age. J Int Med Res2018; 46(3): 1249–1253.
49.
CoccoESarduCGalloP, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: The FEMIMS study. Mult Scler2008; 14(9): 1225–1233.
50.
TuinJSandersJSvan BeekAP, et al. Brief report: Menopause and primary ovarian insufficiency in women treated for antineutrophil cytoplasmic antibody-associated vasculitides. Arthritis Rheumatol2016; 68(4): 986–992.
51.
North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause2012; 19(3): 257–271.
52.
BoveRWhiteCCFitzgeraldKC, et al. Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis. Neurology2016; 87(14): 1457–1463.
